$536.55
Intuitive Surgical, Inc. is a medical technology company that develops and manufactures robotic-assisted surgical systems and instruments.
Market Capitalization | $196.1B |
Revenue TTM | $7.9B |
EBITDA | $2.5B |
Earnings Per Share (EPS) | $6.22 |
PE Ratio | 88.52 |
Profit Margin | 28.51% |
Quarterly Earnings Growth YOY | 0.35% |
Return On Equity TTM | 15.97% |
0.53%
Downside
Day's Volatility :2.75%
Upside
2.24%
43.25%
Downside
52 Weeks Volatility :44.84%
Upside
2.8%
Period | Intuitive Surgical, Inc. | Sector (Health Care) | Index (NASDAQ Composite) |
---|---|---|---|
3 Months | 11.97% | -6.4% | 7.5% |
6 Months | 33.79% | 0.7% | 12.6% |
1 Year | 70.34% | 10.9% | 33.7% |
3 Years | 62.97% | 10.2% | 23.0% |
What analysts predicted
Downside of 0.51%
Insights on Intuitive Surgical, Inc.
Revenue is up for the last 3 quarters, 1.89B → 2.03B (in $), with an average increase of 3.7% per quarter
Netprofit is up for the last 2 quarters, 526.9M → 565.1M (in $), with an average increase of 6.8% per quarter
FY18 | Y/Y Change | |
---|---|---|
Revenue | 3.7B | ↑ 19.03% |
Net Income | 1.1B | ↑ 70.89% |
Net Profit Margin | 30.29% | ↑ 9.2% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 4.5B | ↑ 20.25% |
Net Income | 1.4B | ↑ 22.29% |
Net Profit Margin | 30.8% | ↑ 0.51% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 4.4B | ↓ 2.68% |
Net Income | 1.1B | ↓ 23.11% |
Net Profit Margin | 24.33% | ↓ 6.47% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 5.7B | ↑ 31.01% |
Net Income | 1.7B | ↑ 60.72% |
Net Profit Margin | 29.85% | ↑ 5.52% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 6.2B | ↑ 8.97% |
Net Income | 1.3B | ↓ 22.43% |
Net Profit Margin | 21.25% | ↓ 8.6% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 7.1B | ↑ 14.49% |
Net Income | 1.8B | ↑ 35.98% |
Net Profit Margin | 25.24% | ↑ 3.99% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.8B | ↑ 3.52% |
Net Income | 420.8M | ↑ 18.44% |
Net Profit Margin | 23.96% | ↑ 3.01% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.7B | ↓ 0.69% |
Net Income | 415.7M | ↓ 1.21% |
Net Profit Margin | 23.84% | ↓ 0.12% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↑ 10.59% |
Net Income | 606.2M | ↑ 45.83% |
Net Profit Margin | 31.44% | ↑ 7.6% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 1.9B | ↓ 1.96% |
Net Income | 544.9M | ↓ 10.11% |
Net Profit Margin | 28.82% | ↓ 2.62% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.0B | ↑ 6.31% |
Net Income | 526.9M | ↓ 3.3% |
Net Profit Margin | 26.22% | ↓ 2.6% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Revenue | 2.0B | ↑ 1.4% |
Net Income | 565.1M | ↑ 7.25% |
Net Profit Margin | 27.73% | ↑ 1.51% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 7.8B | ↑ 36.27% |
Total Liabilities | 1.2B | ↑ 12.41% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 9.7B | ↑ 24.04% |
Total Liabilities | 1.4B | ↑ 24.96% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 11.2B | ↑ 14.75% |
Total Liabilities | 1.4B | ↓ 2.67% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 13.6B | ↑ 21.36% |
Total Liabilities | 1.6B | ↑ 13.74% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 13.0B | ↓ 4.29% |
Total Liabilities | 1.9B | ↑ 16.08% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 15.4B | ↑ 19.02% |
Total Liabilities | 2.0B | ↑ 9.82% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 13.9B | ↑ 6.51% |
Total Liabilities | 1.9B | ↑ 10.49% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 14.7B | ↑ 5.82% |
Total Liabilities | 2.1B | ↑ 7.49% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 15.4B | ↑ 4.95% |
Total Liabilities | 2.0B | ↓ 2.15% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 15.8B | ↑ 2.5% |
Total Liabilities | 1.8B | ↓ 12.85% |
Q2 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 16.6B | ↑ 5.19% |
Total Liabilities | 1.9B | ↑ 4.03% |
Q3 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 17.7B | ↑ 6.57% |
Total Liabilities | 2.1B | ↑ 11.47% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.2B | ↑ 2.25% |
Investing Cash Flow | -1.0B | ↓ 377.16% |
Financing Cash Flow | 126.3M | ↓ 106.6% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.6B | ↑ 36.65% |
Investing Cash Flow | -1.2B | ↑ 9.98% |
Financing Cash Flow | -168.4M | ↓ 233.33% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↓ 7.1% |
Investing Cash Flow | -940.6M | ↓ 18.52% |
Financing Cash Flow | -85.7M | ↓ 49.11% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 2.1B | ↑ 40.72% |
Investing Cash Flow | -2.5B | ↑ 161.69% |
Financing Cash Flow | 43.0M | ↓ 150.18% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 1.5B | ↓ 28.65% |
Investing Cash Flow | 1.4B | ↓ 155.69% |
Financing Cash Flow | -2.6B | ↓ 6082.09% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 665.7M | ↑ 79.24% |
Investing Cash Flow | 557.6M | ↓ 2.7% |
Financing Cash Flow | 63.3M | ↓ 116.61% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 548.4M | ↓ 17.62% |
Investing Cash Flow | -446.6M | ↓ 180.09% |
Financing Cash Flow | 61.8M | ↓ 2.37% |
Sell
Neutral
Buy
Intuitive Surgical, Inc. is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Intuitive Surgical, Inc. | 5.02% | 33.79% | 70.34% | 62.97% | 174.68% |
Resmed Inc. | 1.11% | 20.46% | 63.57% | -0.66% | 66.84% |
Becton, Dickinson And Company | -5.62% | -0.58% | -5.6% | -8.0% | -11.65% |
West Pharmaceutical Services Inc | 3.02% | -2.35% | -9.64% | -27.13% | 115.87% |
Alcon Ag | -9.17% | -2.33% | 17.65% | 10.6% | 53.49% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Intuitive Surgical, Inc. | 88.52 | 88.52 | 4.02 | 6.85 | 0.16 | 0.08 | NA | 43.75 |
Resmed Inc. | 32.37 | 32.37 | 1.85 | 7.71 | 0.24 | 0.13 | 0.01 | 35.39 |
Becton, Dickinson And Company | 37.71 | 37.71 | 1.03 | 13.11 | 0.06 | 0.03 | 0.02 | 89.5 |
West Pharmaceutical Services Inc | 46.97 | 46.97 | 5.91 | 6.66 | 0.18 | 0.1 | 0.0 | 37.96 |
Alcon Ag | 36.75 | 36.75 | 3.14 | 3.03 | 0.06 | 0.03 | 0.0 | 43.25 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Intuitive Surgical, Inc. | Buy | $196.1B | 174.68% | 88.52 | 28.51% |
Resmed Inc. | Buy | $35.8B | 66.84% | 32.37 | 23.15% |
Becton, Dickinson And Company | Buy | $64.7B | -11.65% | 37.71 | 7.13% |
West Pharmaceutical Services Inc | Buy | $22.9B | 115.87% | 46.97 | 17.37% |
Alcon Ag | Buy | $42.8B | 53.49% | 36.75 | 11.89% |
Vanguard Group Inc
BlackRock Inc
T. Rowe Price Associates, Inc.
State Street Corp
Morgan Stanley - Brokerage Accounts
FMR Inc
Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the NASDAQ-100 and S&P 500.
Organization | Intuitive Surgical, Inc. |
Employees | 13676 |
CEO | Dr. Gary S. Guthart Ph.D. |
Industry | Health Technology |